Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Alessia Guidolin"'
Autor:
Antonino Marcello Pilia, Lorenzo Salvati, Alessia Guidolin, Francesca Mazzoni, Lorenzo Antonuzzo, Paola Parronchi, Francesco Liotta
Publikováno v:
Swiss Medical Weekly, Vol 154, Iss 3 (2024)
We report the first case of anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis as a systemic immune-related adverse event in a 64-year-old man receiving pembrolizumab to treat advanced lung cancer. The patient experienced
Externí odkaz:
https://doaj.org/article/34f49f41e1b74c49bc744e8d835dd4f8
Autor:
Daniele Lavacchi, Simone Polvani, Antonio Taddei, Federico Scolari, Luca Messerini, Enrico Caliman, Luca Moraldi, Alessia Guidolin, Gian Luca Grazi, Andrea Galli, Serena Pillozzi, Lorenzo Antonuzzo
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionPancreatic adenocarcinoma (PC) is one of the most lethal malignancies; even after resection the patients’ 5-year disease-free survival (DFS) is lower than 26%. The genetic mutational landscape of PC is dominated by activating KRAS mutat
Externí odkaz:
https://doaj.org/article/efcffb8b6c89433990e68a34e3066f61
Autor:
Daniele Lavacchi, Stefania Gelmini, Adele Calabri, Gemma Rossi, Lisa Simi, Enrico Caliman, Irene Mancini, Francesca Salvianti, Giulia Petroni, Alessia Guidolin, Federico Scolari, Luca Messerini, Serena Pillozzi, Pamela Pinzani, Lorenzo Antonuzzo
Publikováno v:
Heliyon, Vol 9, Iss 11, Pp e21853- (2023)
The detection of RAS mutations and co-mutations in liquid biopsy offers a novel paradigm for the dynamic management of metastatic colorectal cancer (mCRC) patients.Expanding the results of the prospective OMITERC (OMIcs application from solid to liqu
Externí odkaz:
https://doaj.org/article/55c53e59b359422f8cc0c0cf89aff599
Autor:
Daniele Lavacchi, Sara Fancelli, Eleonora Buttitta, Gianmarco Vannini, Alessia Guidolin, Costanza Winchler, Enrico Caliman, Agnese Vannini, Elisa Giommoni, Marco Brugia, Fabio Cianchi, Serena Pillozzi, Giandomenico Roviello, Lorenzo Antonuzzo
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 5, p 4877 (2023)
Resectable gastric or gastroesophageal (G/GEJ) cancer is a heterogeneous disease with no defined molecularly based treatment strategy. Unfortunately, nearly half of patients experience disease recurrence despite standard treatments (neoadjuvant and/o
Externí odkaz:
https://doaj.org/article/da243fc2fb13446295c7091734a2d467
Autor:
Daniele Lavacchi, Giandomenico Roviello, Alessia Guidolin, Silvia Romano, Jacopo Venturini, Enrico Caliman, Agnese Vannini, Elisa Giommoni, Elisa Pellegrini, Marco Brugia, Serena Pillozzi, Lorenzo Antonuzzo
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 6, p 5840 (2023)
The management of patients with metastatic colorectal cancer (mCRC) has the continuum of care as the treatment paradigm. To date, trifluridine/tipiracil, a biochemically modulated fluoropyrimidine, and regorafenib, a multi-kinase inhibitor, remain th
Externí odkaz:
https://doaj.org/article/1ea5422ad7d94ae08facba6e673419bb